




Challenges and Opportunities to Conduct Cancer Care Research in China: 
Experience from a Pilot Project  
 




Background: Cancer has become the leading cause of death in China. Effective cancer control and 
population science research programs are desperately needed in China. The China Medical Board (CMB) 
funding has provided us with an opportunity to build a research team specializing in cancer care utilization 
and access research and demonstrate the usefulness of the accrued data. The CMB-funded project will 
describe patterns of cancer screening, incidence, and treatment in Shandong Province in China and 
enable the researchers to understand possible causes of disparities in cancer control in China. 
 
Findings: Although CMB projects do not provide salary support for affiliated American faculty, they do 
provide Chinese scholars in the U.S. an excellent opportunity to help improve health care in China. There 
are many challenges and opportunities in health care service and utilization research in China. For 
example, public data for cancer care research does not exist. We had to acquire secondary data from 
several governmental organizations andreconciled regional variations in data management. After 
acquiring all the data, we could create the most comprehensive cancer access, utilization, and outcomes 
research database to date in China and possibly expand this research in Shandong and other provinces. 
Students and analysts need to be trained to ensure the confidentiality of data linked to personal identifiers 
of patients and providers. At the same time, users need to learn how to manipulate and analyze large 
scale, messy, secondary data.  
 
Discussion: We hope that the key findings will identify innovative scientific opportunities to improve cancer 
control and reduce inequities in communities. We intend to prepare manuscripts and reports in Chinese to 
disseminate findings to communities, policy makers, health care providers, and  the scientific community. 
From the policy perspective, this study is a demonstration project drawing policy makers’ attention to the 
importance of comprehensive cancer prevention and control data collection, both for accurate 
assessment and informed decision making with a high likelihood to effect desired change. 
 




Dr. Yao: I am a health services and policy researcher primarily interested in cancer care and 
based in the U.S. My current research is supported by the National Cancer Institute and the 
Komen Breast Cancer Foundation and focuses on cancer care in older American patients.  I 
initiated my research in cancer care in China as a PhD student when I was at The Pennsylvania 
State University but could not find any cancer related public data. During my last semester of 
PhD training, I saw the call for applications for Health Policy and Systems Sciences Open 
Competition projects on the China Medical Board (CMB) website. The project required a 
principle investigator from one of 17 Chinese universities. I was doubtful that any Chinese 
researchers would be interested in writing a CMB proposal with a PhD candidate from the US 
and did not know any health policy researchers in these 17 universities. However, the China 
Health Policy and Management Society (CHPAMS) monthly emails listed Shandong University’s 
recruitment information and contact person, Dr. Xiaojie Sun. I contacted Dr. Sun who was very 
interested in collaborating. We exchanged several emails and had phone discussions, which 




We wrote and submitted the letter of intent or pre-proposal at the end of March 2013. CMB 
received 119 pre-proposals and in May we were notified that we were one of 25 teams invited 
to submit a full proposal in June. In order to make the team stronger, I invited several cancer 
care researchers and physicians to serve as consultants and Dr. Sun invited administrators at 
local cancer hospitals to join the research team. Reviewers liked our ideas and research design 
but were skeptical about the feasibility of the data collection because no published studies 
have used a similar data collection plan in China. We provided additional data acquisition and 
analysis information in the revision and were notified in December that they would receive $150K 
to study “Patterns of Cancer Screening, Incidence, and Treatment and Disparities in China.” 
 
Cancer in China 
 
Cancer is the number one killer in China, the most feared and most expensive health condition. 
Evidence from well-designed studies reveals the heavy population burden; cancer has become 
the leading cause of death in China (374.1 per 100,000 person-years) [1]. Both cancer incidence 
and mortality in China are increasing [2]. The most recent data show that 13% of deaths in China 
were caused by malignant neoplasm and every minute, six people in China are diagnosed with 
cancer [2]. However, relatively few resources have been dedicated to cancer prevention and 
control research. In contrast, in the United States, the Division of Cancer Control and Population 
Sciences was established in 1997 to enhance the US National Cancer Institute’s (NCI) ability to 
alleviate the burden of cancer through research in epidemiology, behavioral sciences, health 
services, surveillance, and cancer survivorship. Since that time, the division has grown and 
evolved into the model for cancer control research. Most NCI designated cancer centers in the 
US have a cancer control and prevention research program that aims to generate basic 
knowledge about how to monitor and change individual and collective behavior and cancer 
care practice. This provides a path for knowledge translation into practice and policy rapidly, 
effectively, and efficiently. This project aims to promote similar pervasive cancer prevention and 
control research in China, tailored to the needs and context in China.  
 
The project officially started in January 2014. The project has two phases: a pilot phase and a 
main study. The one-year pilot study aims to examine the completeness and accuracy of 
population based secondary data. In addition, the pilot study includes the development and 
testing of a survey questionnaire for patient interviews. This paper reports the challenges and 





CMB encourages collaboration between Chinese and overseas researchers 
 
CMB is a highly focused independent American foundation targeting its grant and support 
activities to “carefully selected Asian institutions”, especially a small number of Chinese 
universities. CMB encourages overseas researchers to establish relationships directly with CMB-
affiliated Chinese and Asian institutions. They believe that all 11 funded projects in the 2013 cycle 
have a research team that crosses country boundaries. Since CMB supports very few Chinese 
institutions, oversea researchers may have a hard time finding a collaborator if he or she wants 
to initiate a CMB project, especially if he or she has never worked with Chinese researchers 
before. The China Health Policy and Management Society (CHPAMS) can possibly play a role to 






CMB grant is relatively small for soft-money faculty 
 
We have to use $150,000 (total cost) to cover the expenses of a three-year research project 
requiring both primary and secondary data collection. Compared to an NIH grant, we are using 
an R03 grant amount to do an R01 project. Although Dr. Sun is actually running the project, Dr. 
Yao has to spend substantial time in designing the study and assisting with research 
implementation. For those in a soft-money faculty position, CMB grant money will not cover 
salary and may not be a cost-effective way to get tenured in a medical school in the U.S. 
However, cancer care policy research is really important and urgent in China and could save 
lives. We hope that our research will lead to policies directed to reducing cancer care disparities, 
improving quality of care, and controlling treatment costs. Other funding sources may also 
support American faculty to study health policy in China, but the amount of funding is not 
significantly larger than the CMB grant. In order to cover my salary, I have to apply for other 
grants to study American healthcare issues at the same time. 
 
The review process is smooth and efficient 
 
We received brief comments about our pre-proposal. Those comments were encouraging but 
not very helpful in developing the full proposal. Three reviewers provided comments on their full 
proposal. Reviewers’ comments were encouraging, but only one reviewer provided detailed 
comments and suggestions besides the scores on significance, innovation, and feasibility. We 
basically addressed all the reviewers’ concerns by adding more information and references to 
the revision. It took about 10 months from drafting the pre-proposal to receiving the grant 
notification. We did not need to deal with the burdensome paperwork that NIH requires. CMB 
sent the award funding on time so we could allocate funds to kick off the project right away. We 
feel the whole process was transparent, smooth, and efficient. CMB announced the review 
results on their Weibo account. Proposal templates were provided when the call was 
announced, which we found very helpful. Readers can refer to the 2013 October issue of China 
Health Review for more information about the review process. Three grantees have provided 
their opinions from the perspective of China-based faculty. 
 
The key to success: two committed collaborators 
 
We had not worked jointly when we decided to write the proposal together. We had many 
virtual meetings through Skype and QQ while writing the proposal. We both committed to 
designing a rigorous study. Dr. Yao wanted to introduce his cancer care research into China, 
and Dr. Sun had to evaluate feasibility and discuss the project with many other researchers and 
administrators in China to find an effective way to implement the research. Although this is a 
three-year project, we are determined to develop and promote cancer care and policy 
research in China. We plan to offer our data and data analysis training to other Chinese 
researchers in the third year. With Dr. Sun’s help and guidance, Dr. Yao has learned a lot in the 
past year about the Chinese health care system and the way to conduct academic research in 
China. Although most Chinese speaking researchers in the US were born and raised in Mainland 
China, they may lack basic knowledge about China healthcare since China is changing so fast. 
Commitment to rigorous health care research has kept our heads up and feet on the ground. 
 
Cancer care is understudied in China 
 
Cancer incidence and mortality rates have been analyzed in China, while the patterns of 
cancer screening, treatment, and disparities have not been rigorously examined. China 
National Cancer Center (CNCC) is a bureau (jú) level non-government organization affiliated 
with the National Health and Family Planning Commission (NHFPC). To our knowledge, CNCC, 
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established several years ago, has not done much population based cancer care research 
through either extramural or intramural programs. Although cancer care physicians in cancer 
hospitals and general hospitals are motivated to do research and to publish, they are more likely 
to be involved in basic and clinical science research. Not many health services and policy 
researchers in China study cancer care, because they need to have substantial clinical 
knowledge of cancer or collaborate closely with cancer doctors. We are optimistic that we can 
find physician collaborators in China as long as we can help them publish in highly ranked 
clinical science or health care journals. 
 
Data acquisition is the most difficult job 
 
There is no public data at all for cancer care and policy research in China. We identified all 
possible cancer related data sources, which were mostly collected for administrative purposes 
rather than for research. We then found the data source owner organizations and used the 
personal connections in Shandong to establish a working relationship with these owner 
organizations. We are collecting data from five rural counties and one metropolitan area, since 
there is not a provincial level organization that can provide data from all study regions. We 
collaborate with three or four organizations in each county or city. In addition, we have found 
regional variations in data management. Same data may be managed by different 
organizations in different places. Dr. Sun has to spend enormous amount of time and efforts on 
trust building for the research collaboration. Obtaining secondary data from government 
organizations is difficult from any position on the career ladder. It is not easy for a full professor, a 
center director, or a dean. Dr. Yao has consulted a well-known faculty who returned to China a 
decade ago from the US. There is no better way than requesting data while conversing around 
the dining table. It is extremely difficult to acquire data in a province or an area if the researcher 
does not have any personal connections in healthcare related sectors. If we can demonstrate 
the value of cancer care research through this project, it may be possible to get political 
support for data acquisition from the provincial government or the central government in the 
future. For example, we could create the largest cancer care research database in the world if 
Shandong provincial government supports us to collect data from the entire Shandong province 
(100 million population). This vision motivates the whole team to work diligently. 
 
Data safety and analysis are challenging 
 
We will receive data with personal identifiers and information about the providers. Since the 
data will only be stored and analyzed in China, this study received expedited review in Virginia 
Commonwealth University and full review in Shandong University. Dr. Yao has trained students to 
ensure the confidentiality of individuals included in the data. It is also important to consider the 
privacy of providers, because unless cancer physicians and hospitals’ privacy is protected, it 
could compromise their willingness to cooperate in the future. None of us has ever used cancer 
related data from so many organizations. Although Dr. Yao has rich experience with similar large 
data sets in the US, we expect the incoming data will be different in terms of structure, 
completeness, and regional variations. Dr. Yao has discovered several limitations in the data. For 
example, the stage of diagnosis is missing for most cancer patients in the cancer registry data. 
Therefore, we have to find other data sources to supplement the registry data. In addition, we 
do not have skilled data analysts or research assistants to do statistical programming. Junior 
faculty members in China are normally not eligible to formally mentor PhD students. Their 
mentees are master level students who often lack rigorous training in programming, data 
analyses, and statistics or econometrics. They have limited experience with messy, large 
secondary data. The bright side is that the data will include patients younger than 65 who are 
excluded from US studies because of data limitations. Also data owners are making efforts to 




Publish or perish 
 
Both American and Chinese universities require research faculty to publish in reputable English 
journals. We think it is relatively hard to publish non-US studies in US-based health policy or clinical 
journals such as Medical Care, Health Affairs, Health Services Research, Journal of Clinical 
Oncology, and Cancer. We may have a better chance of publishing the results from this study in 
UK-based journals such as some BMC journals, which are not popular journals for American 
health policy researchers. Similarly, we expect that our research will only have a slim chance of 
being accepted as oral presentations at premier health policy research conferences such as 
AcademyHealth Annual Research Meeting and clinical conferences such as American Society 
of Clinical Oncology Annual Meeting. Sometimes publishing in English journals is not directly 
aligned with the non-academic goals of a research projects in China. We want to identify 
innovative scientific opportunities to improve cancer control and reduce inequities in 
communities experiencing an excess burden of cancer. We want to disseminate findings to 
communities, policy makers, and health care providers and to the scientific community. The key 
findings of this project will be submitted to the NHFPC through some of Dr. Yao’s ex-colleagues. 
In order to accomplish these goals, we want to write Chinese articles and reports. Dr. Yao is not 
confident that Chinese publications will help his career development but believes that it is the 
right thing to do. 
 
Example results from the pilot survey data 
 
We collected both primary and secondary data in this project. We also conducted a survey on 
the lasting effects of treatment on employment, finances, health insurance coverage, and life in 
general. The pilot survey in Feicheng county of Shandong revealed that most breast patients 
were diagnosed when cancer symptoms were present, while most breast cancer patients in the 
US were diagnosed through screening.  [3] We have also asked cancer survivors if the cancer 
experience had any positive impact on their life (Table 1). It seems that US survivors responded 
more positively to the cancer experience than survivors in Feicheng, China [4]. Chinese cancer 
patients may be sicker than US survivors after diagnosis and treatment. 
 
Table 1. Positive Response to Cancer Experience 
 
Have any of the following been 
positive things about your experiences 
with your cancer, its treatment, or the 
lasting effects of that treatment? 
Feicheng, China 
(N=148) 
US (MEPS data, 
N＝1,419) 
It has made me a stronger person 35.1% 58.8% 
I can cope better with life’s 
challenges 
44.6% 59.4% 
It became a reason to make positive 
changes in my life 
23.0% 57.2% 




Cancer has become the leading cause of death in China. The patterns of cancer screening, 
treatment, and disparities have not been rigorously examined. In addition, cancer care costs 
remain unexamined with relatively rigorous methods in China. We believe that effective cancer 
control and population science research programs are desperately needed in China, which 
motivated us to collaborate on promoting cancer care and policy research. CMB provides a 
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good opportunity to build up a research team specializing in cancer care research. Although 
CMB projects do not provide salary support for American faculty, they provide Chinese scholars 
in the US an excellent opportunity to help improve health care in China. From the economic 
perspective, health care research in China may have a greater impact on people’s wellbeing 
than in the United States if the effect of research on health has reached the point of diminishing 
returns in the US. 
 
This project will clarify the pattern of cancer screening, incidence, and treatment in China and 
facilitate our understanding of possible causes of disparities in cancer control. We will identify 
new and innovative scientific opportunities to improve cancer control and reduce inequities in 
communities experiencing an excess burden of cancer. Disseminating the data and methods of 
data analysis in the Chinese community will invite others to do the same. From the policy 
perspective, this study is a demonstration project drawing policy makers’ attention to the power 
and utility of data collection on cancer prevention and control. We hope interests from the 
academia and the government will lead China to increase cancer control and population 
science research. There are many challenges and opportunities in this type of research project. 
First, China lacks of public data for cancer care related research. We had to acquire several 
different types of secondary data from multiple governmental organizations. We also found 
regional variations in data management. Once we acquire all the data, we could create the 
most extensive cancer care research database in China to date and possibly expand this 
research in Shandong and other provinces. Since we receive a lot of data with personal 
identifiers of patients and providers, they trained students and analysts to ensure data 
confidentiality. We have also discovered limitations of the data. We have to train students and 
analysts to use large scale, messy secondary data. It is relatively hard to publish non-US studies in 
US-based health policy or clinical journals. Despite of all these challenges, we hope that the key 
findings will identify innovative scientific opportunities to improve cancer control and reduce 
inequities in communities.  We also intend to write Chinese articles and reports to disseminate 
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